Altimmune/$ALT
1D1W1MYTD1Y5YMAX
Capital at risk
About Altimmune
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
- Ticker
- $ALT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 57
- Headquarters
- Gaithersburg, United States
- Website
- altimmune.com
Altimmune Metrics
BasicAdvanced
$642M
-
-$0.73
0.17
-
Price and volume
Market cap
$642M
Beta
0.17
52-week high
$6.44
52-week low
$2.56
Average daily volume
4.1M
Financial strength
Current ratio
26.783
Quick ratio
26.368
Long term debt to equity
0.075
Total debt to equity
0.076
Interest coverage (TTM)
-27.92%
Profitability
EBITDA (TTM)
-98.634
Gross margin (TTM)
-215,138.71%
Net profit margin (TTM)
-296,000.00%
Operating margin (TTM)
-318,493.55%
Management effectiveness
Return on assets (TTM)
-17.20%
Return on equity (TTM)
-28.87%
Valuation
Price to revenue (TTM)
13,469.388
Price to book
1.35
Price to tangible book (TTM)
1.35
Price to free cash flow (TTM)
-5.448
Free cash flow yield (TTM)
-18.35%
Free cash flow per share (TTM)
-0.606
Growth
Revenue change (TTM)
55.00%
Earnings per share change (TTM)
-38.09%
3-year revenue growth (CAGR)
-27.40%
3-year earnings per share growth (CAGR)
-23.62%
What the Analysts think about Altimmune
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Analyst projections of the future price of Altimmune stock.
Bulls say / Bears say
Pemvidutide has reached a global, registrational Phase 3 trial in MASH after positive Phase 2b findings and FDA Breakthrough Therapy designation. PERFORMA is designed to test both fibrosis improvement and MASH resolution, giving Altimmune a credible route towards accelerated approval. (GlobeNewswire, BioSpace)
The 100-patient RECLAIM Phase 2 trial met its primary endpoint, with pemvidutide significantly reducing heavy drinking days versus placebo. Positive results on WHO risk-drinking levels, zero heavy drinking days and the objective PEth biomarker give Altimmune several signals to take into its FDA meeting for a potential AUD Phase 3 programme. (Altimmune)
New 48-week IMPACT analyses showed consistent improvements in non-invasive markers of MASH activity and fibrosis, alongside better weight, lipid, waist-circumference and blood-pressure measures. This supports pemvidutide’s positioning as a treatment that could address both liver disease and its underlying metabolic drivers. (Altimmune, Altimmune)
Altimmune’s $519 million cash position funds the MASH programme only through its 2029 readout, not a potential Phase 3 AUD trial. The company will need non-dilutive funding, debt, a partner or potentially further equity to pursue that second major opportunity. (Investing.com, StockAnalysis)
There is no near-term commercial income: Q2 revenue was $0 and the net loss was $22.8 million, while the key MASH readout is expected in 2029. That leaves investors exposed to years of trial execution and continued cash burn before any product revenue. (Longbridge, TradingKey)
Pemvidutide still has to prove clear commercial differentiation in a crowded MASH field. William Blair analysts said the Phase 2b results showed therapeutic activity but not clear differentiation from Rezdiffra, survodutide and Lilly’s competing programmes. (MedCity News)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Altimmune Financial Performance
Revenues and expenses
Altimmune Earnings Performance
Company profitability
Upcoming events
No upcoming events
Altimmune News
AllArticlesVideos
Funds containing Altimmune
AllUSDGBPEUR
Fund name | Fund size | $ALT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.